Table 1.
Baseline characteristics of all patients stratified for HGP
| Total N = 690 | dHGP N = 173 | Non-dHGP N = 517 | p-value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 445 (65%) | 109 (63%) | 336 (65%) | 0.637 |
| Female | 245 (36%) | 64 (37%) | 181 (35%) | |
| Age | ||||
| Median (IQR) | 65 (58–71) | 65 (56–72) | 64 (58–71) | 0.984 |
| ASA | ||||
| ASA I-II | 617 (91%) | 153 (89%) | 464 (91%) | 0.351 |
| ASA > II | 63 (9%) | 19 (11%) | 44 (9%) | |
| Missing | 10 patients | |||
| Primary tumour characteristics | ||||
| Location | ||||
| Right-sided | 116 (17%) | 30 (17%) | 86 (17%) | 0.927 |
| Left-sided | 302 (44%) | 76 (44%) | 226 (44%) | |
| Rectum | 256 (37%) | 62 (36%) | 194 (38%) | |
| Double tumour | 16 (2%) | 5 (3%) | 11 (2%) | |
| pTumour stage | ||||
| pT0-2 | 134 (20%) | 39 (23%) | 95 (19%) | 0.239 |
| pT3-4 | 546 (80%) | 132 (77%) | 414 (81%) | |
| Missing | 10 patients | |||
| Nodal status | ||||
| N0 | 270 (40%) | 79 (47%) | 191 (38%) | 0.035* |
| N+ | 407 (60%) | 90 (53%) | 317 (62%) | |
| Missing | 13 patients | |||
| Adjuvant chemotherapy primary tumour | ||||
| No | 587 (85%) | 160 (93%) | 427 (83%) | 0.002* |
| Yes | 103 (15%) | 13 (8%) | 90 (17%) | |
| CRLM characteristics | ||||
| Synchronous CRLM | ||||
| No | 329 (48%) | 264 (51%) | 65 (38%) | 0.002* |
| Yes | 361 (52%) | 253 (49%) | 108 (62%) | |
| Disease-free interval (months) | ||||
| Median (IQR) | 2 (0–17) | 0 (0–13) | 5 (0–18) | 0.006* |
| Number of CRLM | ||||
| Median (IQR) | 2 (1–4) | 2 (1–4) | 2 (1–4) | 0.886 |
| Size of largest CRLM (cm) | ||||
| Median (IQR) | 3.1 (2.0-4.5) | 2.5 (1.8–4.2) | 3.3 (2.3–4.8) | < 0.001* |
| Missing | 2 patients | |||
| Preoperative CEA (µg/L) | ||||
| Median (IQR) | 14.0 (4.7–50.0) | 7.6 (3.2–30.0) | 16.2 (5.1–53.0) | < 0.001* |
| Missing | 28 patients | |||
| Fong CRS | ||||
| Low | 408 (61%) | 101 (61%) | 307 (61%) | 0.924 |
| High | 262 (39%) | 64 (39%) | 198 (39%) | |
| Incomplete CRS | 20 patients | |||
| Bilobar metastases | ||||
| No | 418 (61%) | 106 (61%) | 312 (60%) | 0.830 |
| Yes | 272 (39%) | 67 (39%) | 205 (40%) | |
| Preoperative CTx | ||||
| No | 365 (53%) | 68 (39%) | 297 (57%) | < 0.001* |
| Yes | 325 (47%) | 105 (61%) | 220 (43%) | |
| Resection margin | ||||
| R0 | 585 (85%) | 158 (92%) | 427 (83%) | 0.004* |
| R1 | 102 (15%) | 14 (8%) | 88 (17%) | |
| Missing | 3 patients | |||
| Extra hepatic disease | ||||
| No | 629 (91%) | 157 (91%) | 472 (91%) | 0.827 |
| Yes | 61 (9%) | 16 (9%) | 45 (9%) | |
| Major liver resection | ||||
| <3 complete segments | 455 (66%) | 122 (71%) | 333 (64%) | 0.142 |
| ≥3 complete segments | 235 (34%) | 51 (30%) | 184 (36%) | |
| Recurrence after first resection CRLM | ||||
| No | 198 (29%) | 70 (40%) | 128 (25%) | < 0.001* |
| Yes | 492 (71%) | 103 (60%) | 389 (75%) | |
*Indicates significant p-value
Percentages do not always add up to 100% due to rounding
ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, CRLM colorectal liver metastases, CRS clinical risk score, CTx Chemotherapy, HGP histopathological growth pattern, IQR interquartile range, R1 irradical resection margin